The firm specializes in driving investor interest
SALT LAKE CITY, June 26, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCQB:NUMD), a medical device company which investigates and develops nitric oxide applications of new technologies in the medical field, has selected s2s Public Relations firm as their partner. The Seattle-based firm provide immediate value through tailored messaging, earned media placements and developing compelling content for technology, biotech, and traditional clients. The firm produces compelling public relations campaigns and social media strategies that will help drive awareness of Nu-Med Plus and its innovative approach to nitric oxide delivery. The team of former journalists, startup executives, and public relations practitioners will further help guide the expansion of Nu-Med Plus, Inc. and its Inhaled Nitric Oxide(INO) products throughout the financial arena.
“Nu-Med Plus has an important story to tell about our technology which holds the potential to revolutionize and expand the Inhaled Nitric Oxide(INO) marketplace,” said Nu-Med Plus President Jeff Robins. “Our new strategic partnership with s2s Public Relations gives us the right tools to start sharing that story and driving increased value for our investors.”
Inhaled Nitric oxide is a medically essential gas that is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns) and may have future applications for a variety of other diseases and complications that are currently being investigated. Nu-Med Plus has already secured one patent and has two other patents pending on propriety technologies which provide a unique competitive advantage for the company. The company currently has four Inhaled Nitric Oxide products in its pipeline which could impact hundreds of millions of patents around the world.
Media Contact: email@example.com
About Nu-Med Plus, Inc.: Nu-Med Plus, Inc., founded in 2011, is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com.
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.
© 2018 GlobeNewswire, Inc. All Rights Reserved.